Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues (ATSA)
2023-505884-35-00Phase 4Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, open-label trial of lutetium Lu 177 dotatate in apudoma (NET) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Absorbed dose in target lesions. Planned start Jan 2024; status: authorised.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2023-505884-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505884-35-00.